London, June 18, 2014: MRC Technology, a technology transfer organisation, announced today that it has sold to Pfizer Inc. its melanocortin receptors (MCRs) programme, which includes a set of small
CORAL GABLES, Fla., June 18, 2014. Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX), a specialty pharmaceutical company focused on developing safe and effective approved medicines targeting orphan neuromuscular and neurological diseases, announced
Merrimack Pharmaceuticals, Inc., a biopharmaceutical company focused on the discovery and development of novel treatments for cancer, today announced that it has raised $77 million in a Series G private
Sanford-Burnham Medical Research Institute (Sanford-Burnham) has entered into a collaboration with Ortho-McNeil-Janssen Pharmaceuticals, Inc., (OMJPI) to discover compounds for Alzheimer’s disease and major psychiatric disorders.
